Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Scalp psoriasis is an autoimmune skin condition, while dandruff is often the result of oily or greasy hair. Here are the key ...

Scalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

UCB's Bimzelx shows sustained efficacy in psoriasis and hidradenitis suppurativa, with high skin clearance rates and improved ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

UCB, a global biopharmaceutical company, today announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with ...